Effect of Lactase Enzyme chewable tablets on Hydrogen Breath Excretion and Intestinal Symptoms in patients of Lactose Malabsorption and Intolerance: A Crossover double-blind placebo-controlled study

开始日期2018-02-25

申办/合作机构-

CTRI/2017/12/010930 / CompletedN/A

Efficacy and Safety of Lactase in Infantile Colic: A Randomized Placebo Controlled Trial

开始日期2018-01-01

申办/合作机构-

100 项与半乳糖苷酶(Recordati SpA) 相关的临床结果

登录后查看更多信息

100 项与半乳糖苷酶(Recordati SpA) 相关的转化医学

登录后查看更多信息

100 项与半乳糖苷酶(Recordati SpA) 相关的专利（医药）

登录后查看更多信息

379

项与半乳糖苷酶(Recordati SpA) 相关的文献（医药）

2024-10-01·JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Lactase for infantile colic: A systematic review of randomized clinical trials

Review

作者: Deboni, Mariana ; de Carlos, Gabriel Assis ; Cezar, Alessandra Bacelar ; Bassan, Amanda Santiago ; Nau, Angélica Luciana

Abstract:

Infantile colic is excessive crying for no apparent reason in an otherwise healthy infant. Although its physiopathology is not completely understood, therapies usually target gastrointestinal symptoms. This systematic review of randomized controlled trials (RCTs) analyzes the efficacy of lactase supplementation in infantile colic. PubMed, Embase, and Cochrane were searched for RCTs evaluating lactase supplementation in infants up to 6 months old with infantile colic. Out of six RCTs including 394 patients, three reported a significantly shorter crying time in the lactase group than in the placebo group, while the other three found no significant difference between groups. Of the two studies that performed the hydrogen breath test, only one reported a significant reduction in exhaled hydrogen levels. The pharmacological approach to infantile colic remains debatable, and new studies with standardized diagnostic criteria and outcomes are required to guide lactase supplementation in clinical practice.

2024-09-01·FOOD AND CHEMICAL TOXICOLOGY

Comparison of the developmental effects of lactase or bisphenol A antibody immobilized polycaprolactone/silk fibroin nanofibers on zebrafish embryos

Article

作者: Emekli-Alturfan, Ebru ; Tunalı Akbay, Tuğba ; Ünal, İsmail ; Sivas, Güzin Göksun ; Gürel-Gökmen, Begüm

This study aimed to detect the biocompatibility of bioactivated polycaprolactone/silk fibroin-based nanofibers in vivo using zebrafish embryos. Anti-Bisphenol A (BPA) antibody or lactase enzyme was immobilized on electrospun nanofibers, for making the nanofiber bioactive. Lactase immobilized nanofiber was developed to hydrolyze lactose and produce milk with reduced lactose. Anti-BPA antibody immobilized nanofiber was developed to remove bisphenol A from liquids. To test the biocompatibility of the bioactive nanofibers, the zebrafish embryos were divided into 4 groups; control, raw nanofiber, lactase immobilized nanofiber, and anti-BPAantibody immobilized nanofiber groups. In nanofiber-based exposure groups; nanofibers were incubated separately in the embryonic development medium. Subsequently, the embryos were kept in these development mediums for 72 h post-fertilization (72 hpf) and their developmental analyzes were performed. At the end of 72 hpf, zebrafish embryos were homogenized. Lipid peroxidation and nitrite oxide levels, and superoxide dismutase and glutathione-S-transferase activities were determined to monitor the disturbance of oxidant-antioxidant balance in zebrafish embryos. Exposure to bioactive nanofibers slightly disrupted the oxidant-antioxidant balance, but this change did not affect the mortality and hatching times of the embryos. In conclusion, zebrafish embryos have been effectively used in biocompatibility testing for bioactive nanofibers suggesting that these materials are biocompatible.

2024-07-01·JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Infant formulas for the treatment of functional gastrointestinal disorders: A position paper of the ESPGHAN Nutrition Committee

Review

作者: Kivelä, Laura ; Luque, Veronica ; Bronsky, Jiri ; Moltu, Sissel J ; Savino, Francesco ; Norsa, Lorenzo ; Hill, Susan ; Verduci, Elvira ; De Pipaon, Miguel Saenz ; Kӧglmeier, Jutta ; Haiden, Nadja ; De Koning, Barbara

Abstract:

Functional gastrointestinal disorders (FGID), such as infant regurgitation, infant colic, and functional constipation, are common and typically physiological phenomena during the early months of an infant's life and account for frequent consultations with pediatricians. Various infant formulas are marketed for their management and are frequently given by parents to infants before a medical consultation. However, the evidence supporting their effectiveness is limited and some have altered nutritional compositions when compared to standard formulas. Thus, these products should only be used under medical supervision and upon medical advice. Marketing and over‐the‐counter sales do not ensure proper medical guidance and supervision. The aim of this position paper is to review the current evidence regarding the safety and efficacy of formulas specifically formulated for addressing regurgitation, colic, and constipation, recognized as FGID. The objective is to provide guidance for clinical management based on the highest quality of available evidence. A wide search using Pubmed, MEDLINE, EMBASE and Cochrane Database of Systematic Reviews was performed including the MESH terms infant formula, colic, constipation, regurgitation, reflux, palmitate, lactase, lactose, magnesium, hydrolyzed protein, prebiotics or probiotics. 752 papers were identified and screened. Finally, 72 papers were included in the paper. In the absence of evidence, recommendations reflect the authors' combined expert opinion. Final consensus was obtained by multiple e‐mail exchange and meetings of the Nutrition Committee. (1) For breastfed infants experiencing FGID such as regurgitation, colic, or constipation, transitioning from breastfeeding to commercial formulas is not recommended. (2) In general, whether an infant is breastfed or formula‐fed, it's crucial to reassure parents that FGIDs are normal and typically do not necessitate treatment or change to a special formula. (3) Thickened formulas, often termed anti‐reflux formulas, may be considered in specific cases of regurgitation. (4) The usage of specialized formulas for infants with colic is not advised due to a lack of clinical evidence. (5) In the case of constipation in infants, the use of formulas enriched with high β‐palmitate and increased magnesium content may be considered to soften the stool. Generally, there is limited evidence supporting the use of specialized formulas for FGID. Breastfeeding should never be discontinued in favor of formula feeding.

项与半乳糖苷酶(Recordati SpA) 相关的新闻（医药）

2024-07-29

·GlobeNewswire-Health Care

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, July 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of a microbiome study demonstrating that beta-glucuronidase is present at similar levels among dog, mouse, and human microbiota as well as within healthy humans and those with Crohn’s disease (CD) and ulcerative colitis (UC). “We are pleased to bolster our growing body of data for PALI-2108. The study completed by CosmosID, which uses direct identification of beta-glucuronidase by multiple databases, indicates that the presence of this enzyme is not significantly different among the species or between healthy and disease human cohorts. This allows the prodrug to break down in the areas of the GI tract where we are trying to deliver the active drug and confirms our previous findings of adequate bioactivation of PALI-2108 in NHV and UC patients’ stool,” commented Dr. Mitch Jones, CMO of Palisade Bio. Publicly available data for dog, mouse, and human whole genome metagenomic sequencing was obtained from the NCBI Sequence Read Archive (https://www-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/sra). These samples were found by searching for metagenomic data for the specific host species and further filtered for Illumina paired-end whole genome sequencing (WGS) data. These data samples were subsampled to 6 million reads each to allow for accurate functional pathway and gene identification while keeping the maximum number of samples for comparison. After subsampling, the samples were uploaded to the CosmosID-HUB (app.cosmosid.com) for functional identification of genes, enzymes, and pathways utilizing the MetaCyc, Gene Ontology, and Enzyme Commission databases. Findings from the study demonstrated that although there are overall significant differences by species among the functional data as a whole, beta-glucuronidase-specific functions are not significant. The superpathway of beta D-glucuronoside degradation does show significant differences by species, but this pathway does not directly identify the enzyme beta-glucuronidase. Beta-D-glucuronoside is the substrate for beta-glucuronidase (MetaCyc pathway), which may imply that the enzyme is present. However, direct identification of beta-glucuronidase by both EC and GO databases indicate that the presence of this enzyme is not significantly different among the species or between healthy and disease human cohorts. Palisade continues to advance PALI-2108 for the treatment of moderate-to-severe UC toward a Phase 1 clinical study, expected to be initiated before the end of 2024. The Company’s PALI-1908 candidate is a microbiota-activated PDE4 inhibitor prodrug that leverages the advancements made with PALI-2108 and is being developed for the treatment of fibro stenotic Crohn’s Disease. About Palisade Bio Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024 and May 13, 2024, respectively. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations ContactJTC Team, LLCJenene Thomas 833-475-8247PALI@jtcir.com Source: Palisade Bio

临床1期微生物疗法

2023-05-02

·PRNewswire

Intoleran Is Helping People Live With IBS

The Dutch Brand's High-Quality Digestive Enzymes Are Reducing Symptoms and Making Life Enjoyable Again FORT LAUDERDALE, Fla., May 2, 2023 /PRNewswire/ -- Irritable bowel syndrome or IBS is a common condition that encompasses a range of dietary concerns. Mayo Clinic defines IBS as "a common disorder that affects the stomach and intestines, also called the gastrointestinal tract." While maintaining the "common" element, John Hopkins offers a slightly different definition, describing IBS as, "a common condition characterized by abdominal discomfort associated with altered bowel movements." The medical site adds that IBS is currently diagnosed using the Rome IV criteria (a formal set of diagnosis guidelines). While IBS is common and involves digestional discomfort, it remains an umbrella term with many symptoms and definitions. This makes diagnosis difficult and solutions even harder to come by — which is where the Dutch health brand Intoleran comes into the picture. Intoleran is known as a creator of digestive enzymes. These supplements support the digestive systems of those suffering from food intolerances by filling in key gaps in organic enzyme production. What many consumers don't realize, however, is that Intoleran's products — especially its comprehensive quatrase forte enzyme formula — can help with IBS, too. "We help those with intolerances digest their food," explains company owner Harmen Treep, "but this approach to digestive support can be broadened to IBS, as well. Often the root causes of IBS stem from an inability to properly break down and digest troublesome foods. When that is the case, our products can provide a clean, safe, and effective form of support." Intoleran's supplements offer elite digestive support through a few key factors: First, they are high-quality products carefully sourced and produced manually following HACCP guidelines in the company's production lab in the Netherlands. Second, Intoleran supplements are clean without unnecessary fillers. The brand's lactase supplement, for instance, consists of the lactase enzyme, a small amount of calcium carbonate as a filler, and the HPMC capsule. That's it. Third, Intoleran is Monash certified. This is a highly sought-after categorization reserved for products that help those with IBS or who struggle to digest FODMAP foods. Intoleran's supplements, especially its quatrase forte, are an excellent way for those with IBS to address their ongoing symptoms. It reduces reactions to trigger foods and minimizes pain and discomfort. "We aren't just helping people with their digestion," Treep declares, "We're enabling them to enjoy life again." About Intoleran Intoleran was founded in the Netherlands in 2008. The Dutch health brand specializes in creating enzyme-based supplements that address a variety of food intolerances, including lactose, fructose, fructans, galactans, and sucrose. Intoleran products assist the digestive system by helping to properly digest food and, consequently, avoid many of the unpleasant side effects that come from food intolerances. To preserve quality and effectiveness, Intoleran only uses ingredients necessary for the effect of the supplements and no unnecessary additives. This allows as many people as possible to use the products without unwanted side effects. Learn more at intoleran.com. Media Contact: Bouke Smeets M: +31(06)23763626 [email protected] SOURCE Intoleran

2022-11-02

·PRNewswire

Malabsorption Syndrome Market Size to Grow by USD 1.55 Bn, Lactose Intolerance to be Largest Revenue-generating Disease Type Segment - Technavio

NEW YORK, Nov. 2, 2022 /PRNewswire/ -- The malabsorption syndrome market size is set to grow by USD 1.55 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 7.73% during the forecast period, according to Technavio. The higher consumption of gluten-containing food is driving the malabsorption syndrome market growth. However, factors such as shifting preferences toward dairy-free alternatives may challenge the market growth. Continue Reading Technavio has announced its latest market research report titled Global Malabsorption Syndrome Market 2022-2026 The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. Read FREE Sample Report Malabsorption Syndrome Market 2022-2026: Segmentation Disease type Lactose intolerance: The lactose intolerance segment will be a significant contributor to market growth during the forecast period. Pharma lactase is a lactase enzyme that is produced by the fermentation of a selected strain of bacteria that hydrolyze lactose. Lactase is available as an over-the-counter prevention drug for lactose intolerance. Diagnostic tests such as lactose intolerance test and hydrogen breath test are used to determine the presence of lactose malabsorption, which is also known as maldigestion. The rising application of such tests is expected to drive the growth of the lactose intolerance segment during the forecast period. Sprue Cystic fibrosis Geography North America: North America will account for 38% of the market's growth during the forecast period. This growth is attributed to factors such as the high consumption of gluten-containing foods and the growing prevalence of celiac diseases. However, market growth in this region will be slower than the growth of the market in Europe and Asia. The US and Canada are the key countries for the malabsorption syndrome market in North America. Europe Asia Rest Of World (ROW) Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Request a FREE PDF Sample Now Malabsorption Syndrome Market 2022-2026: Vendor Analysis and Scope To help businesses improve their market position, Technavio's report provides a detailed analysis of around 25 vendors operating in the market. Some of the major vendors of the malabsorption syndrome market include AbbVie Inc., Ache Laboratorios Farmaceuticos SA, Aspen Pharmacare Holdings Ltd., Bausch Health Companies Inc., Baxter International Inc., COSMO PHARMACEUTICALS NV, Ferring B.V., Koninklijke DSM NV, Lannett Co. Inc., Merck and Co. Inc., Novartis AG, Organon and Co., Perrigo Co. Plc, ProThera Biologics Inc., Sanofi, Tillotts Pharma AG, Xspire Pharma LLC, and Pfizer Inc. The report also covers the following areas : Malabsorption Syndrome Market size Malabsorption Syndrome Market trends Malabsorption Syndrome Market industry analysis This report provides a full list of key vendors, their strategies, and latest developments. Buy Now for detailed vendor information Malabsorption Syndrome Market 2022-2026: Key Highlights CAGR of the market during the forecast period 2022-2026 Detailed information on factors that will assist malabsorption syndrome market growth during the next five years Estimation of the malabsorption syndrome market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the malabsorption syndrome market Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of malabsorption syndrome market vendors Get lifetime access to our Technavio Insights. Subscribe now to our most popular "Basic Plan" billed annually at USD 5000. View 100 reports and download 5 reports monthly! Related Reports Lennox-Gastaut Syndrome Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The introduction of phytochemicals is a key trend. The currently available chemical molecule-based therapies and surgical treatments for LGS are not fully effective in all cases. Phytochemicals are biologically active compounds that are produced from plants. Chronic Fatigue Syndrome Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026: The development of new diagnostic tests for CFS is a key trend. Currently, there is no standard and reliable diagnostic test for the diagnosis of CFS. Recently, researchers at the Stanford University School of Medicine identified a biomarker and developed a blood test for the diagnosis of CFS. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Disease Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Disease Type 5.1 Market segments Exhibit 24: Chart on Disease Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Disease Type - Market share 2021-2026 (%) 5.2 Comparison by Disease Type Exhibit 26: Chart on Comparison by Disease Type Exhibit 27: Data Table on Comparison by Disease Type 5.3 Lactose intolerance - Market size and forecast 2021-2026 Exhibit 28: Chart on Lactose intolerance - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Lactose intolerance - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Lactose intolerance - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Lactose intolerance - Year-over-year growth 2021-2026 (%) 5.4 Sprue - Market size and forecast 2021-2026 Exhibit 32: Chart on Sprue - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Sprue - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Sprue - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Sprue - Year-over-year growth 2021-2026 (%) 5.5 Cystic fibrosis - Market size and forecast 2021-2026 Exhibit 36: Chart on Cystic fibrosis - Market size and forecast 2021-2026 ($ million) Exhibit 37: Data Table on Cystic fibrosis - Market size and forecast 2021-2026 ($ million) Exhibit 38: Chart on Cystic fibrosis - Year-over-year growth 2021-2026 (%) Exhibit 39: Data Table on Cystic fibrosis - Year-over-year growth 2021-2026 (%) 5.6 Market opportunity by Disease Type Exhibit 40: Market opportunity by Disease Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 42: Chart on Market share by geography 2021-2026 (%) Exhibit 43: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 44: Chart on Geographic comparison Exhibit 45: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 China - Market size and forecast 2021-2026 Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 Canada - Market size and forecast 2021-2026 Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 AbbVie Inc. Exhibit 89: AbbVie Inc. - Overview Exhibit 90: AbbVie Inc. - Product / Service Exhibit 91: AbbVie Inc. - Key offerings 10.4 Koninklijke DSM NV Exhibit 92: Koninklijke DSM NV - Overview Exhibit 93: Koninklijke DSM NV - Business segments Exhibit 94: Koninklijke DSM NV - Key news Exhibit 95: Koninklijke DSM NV - Key offerings Exhibit 96: Koninklijke DSM NV - Segment focus 10.5 Lannett Co. Inc. Exhibit 97: Lannett Co. Inc. - Overview Exhibit 98: Lannett Co. Inc. - Product / Service Exhibit 99: Lannett Co. Inc. - Key news Exhibit 100: Lannett Co. Inc. - Key offerings 10.6 Merck and Co. Inc. Exhibit 101: Merck and Co. Inc. - Overview Exhibit 102: Merck and Co. Inc. - Business segments Exhibit 103: Merck and Co. Inc. - Key news Exhibit 104: Merck and Co. Inc. - Key offerings Exhibit 105: Merck and Co. Inc. - Segment focus 10.7 Novartis AG Exhibit 106: Novartis AG - Overview Exhibit 107: Novartis AG - Business segments Exhibit 108: Novartis AG - Key offerings Exhibit 109: Novartis AG - Segment focus 10.8 Organon and Co. Exhibit 110: Organon and Co. - Overview Exhibit 111: Organon and Co. - Product / Service Exhibit 112: Organon and Co. - Key offerings 10.9 Perrigo Co. Plc Exhibit 113: Perrigo Co. Plc - Overview Exhibit 114: Perrigo Co. Plc - Business segments Exhibit 115: Perrigo Co. Plc - Key offerings Exhibit 116: Perrigo Co. Plc - Segment focus 10.10 Pfizer Inc. Exhibit 117: Pfizer Inc. - Overview Exhibit 118: Pfizer Inc. - Product / Service Exhibit 119: Pfizer Inc. - Key news Exhibit 120: Pfizer Inc. - Key offerings 10.11 ProThera Biologics Inc. Exhibit 121: ProThera Biologics Inc. - Overview Exhibit 122: ProThera Biologics Inc. - Product / Service Exhibit 123: ProThera Biologics Inc. - Key offerings 10.12 Sanofi Exhibit 124: Sanofi - Overview Exhibit 125: Sanofi - Business segments Exhibit 126: Sanofi - Key news Exhibit 127: Sanofi - Key offerings Exhibit 128: Sanofi - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 129: Inclusions checklist Exhibit 130: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 131: Currency conversion rates for US$ 11.4 Research methodology Exhibit 132: Research methodology Exhibit 133: Validation techniques employed for market sizing Exhibit 134: Information sources 11.5 List of abbreviations Exhibit 135: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio